Systematic kinome shRNA screening identifies CDK11 (PITSLRE) kinase expression is critical for osteosarcoma cell growth and proliferation

Clinical Cancer Research

Volumn 18, Issue 17, 2012, Pages 4580-4588

  Duan, Zhenfeng ^a   Zhang, Jianming ^b   Choy, Edwin ^a   Harmon, David ^a   Liu, Xianzhe ^a   Nielsen, Petur ^a   Mankin, Henry ^a   Gray, Nathanael S ^b   Hornicek, Francis J ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIN DEPENDENT KINASE; CYCLIN DEPENDENT KINASE 11; POLO LIKE KINASE 1; SHORT HAIRPIN RNA; SMALL INTERFERING RNA; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; CANCER INHIBITION; CANCER SURVIVAL; CELL GROWTH; CELL PROLIFERATION; CELL SURVIVAL; CONTROLLED STUDY; HUMAN; IMMUNOHISTOCHEMISTRY; OSTEOSARCOMA; OSTEOSARCOMA CELL; PHENOTYPE; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; SIGNAL TRANSDUCTION; WESTERN BLOTTING;

ADOLESCENT; ADULT; ANIMALS; APOPTOSIS; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; CHILD; CHILD, PRESCHOOL; CYCLIN-DEPENDENT KINASES; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GENETIC THERAPY; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; MICE; MIDDLE AGED; OSTEOSARCOMA; RNA, SMALL INTERFERING; TRANSPLANTATION, HETEROLOGOUS;

EID: 84865794821     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-12-1157     Document Type: Article

References (38)

1. Geller DS, Gorlick R. Osteosarcoma: a review of diagnosis, management, and treatment strategies. Clin Adv Hematol Oncol 2010;8:705-18.
2. Chou AJ, Geller DS, Gorlick R. Therapy for osteosarcoma: where do we go from here? Paediatr Drugs 2008;10:315-27.
3. Bielack SS, Marina N, Ferrari S, Helman LJ, Smeland S, Whelan JS, et al. Osteosarcoma: the same old drugs or more? J Clin Oncol 2008;26:3102-3; author reply 3104-5.
4. O'Day K, Gorlick R.Novel therapeutic agents for osteosarcoma. Expert Rev Anticancer Ther 2009;9:511-23.
5. Gorlick R. Current concepts on the molecular biology of osteosarcoma. Cancer Treat Res 2009;152:467-78.
6. Zhang J, Yang PL, Gray NS. Targeting cancer with small molecule kinase inhibitors. Nat Rev Cancer 2009;9:28-39.
7. Lapenna S, Giordano A. Cell cycle kinases as therapeutic targets for cancer. Nat Rev Drug Discov 2009;8:547-66.
8. Krause DS, Van Etten RA. Tyrosine kinases as targets for cancer therapy. N Engl J Med 2005;353:172-87.
9. Shapiro GI. Cyclin-dependent kinase pathways as targets for cancer treatment. J Clinical Oncol 2006;24:1770-83.
10. Malumbres M, Harlow E, Hunt T, Hunter T, Lahti JM, Manning G, et al. Cyclin-dependent kinases: a family portrait. Nat Cell Biol 2009;11:1275-6.
11. Duan Z, Ji D, Weinstein EJ, Liu X, Susa M, Choy E, et al. Lentiviral shRNA screen of human kinases identifies PLK1 as a potential therapeutic target for osteosarcoma. Cancer Lett 2010;293:220-9.
12. Yang C, Ji D, Weinstein EJ, Choy E, Hornicek FJ, Wood KB, et al. The kinase Mirk is a potential therapeutic target in osteosarcoma. Carcinogenesis 2010;31:552-8.
13. Duan Z, Weinstein EJ, Ji D, Ames RY, Choy E, Mankin H, et al. Lentiviral short hairpin RNA screen of genes associated with multidrug resistance identifies PRP-4 as a new regulator of chemoresistance in human ovarian cancer. Mol Cancer Ther 2008;7:2377-85.
14. Takei Y, Kadomatsu K, Yuzawa Y, Matsuo S, Muramatsu T. A small interfering RNA targeting vascular endothelial growth factor as cancer therapeutics. Cancer Res 2004;64:3365-70.
15. Filleur S, Courtin A, Ait-Si-Ali S, Guglielmi J, Merle C, Harel-Bellan A, et al. SiRNA-mediated inhibition of vascular endothelial growth factor severely limits tumor resistance to antiangiogenic thrombospondin-1 and slows tumor vascularization and growth. Cancer Res 2003;63:3919-22.
16. Fujii T, Saito M, Iwasaki E, Ochiya T, Takei Y, Hayashi S, et al. Intratumor injection of small interfering RNA-targeting human papillomavirus 18 E6 and E7 successfully inhibits the growth of cervical cancer. Int J Oncol 2006;29:541-8.
17. Dormoy V, Beraud C, Lindner V, Thomas L, Coquard C, Barthelmebs M, et al. LIM-class homeobox gene Lim1, a novel oncogene in human renal cell carcinoma. Oncogene 2011;30:1753-63.
18. Friedman E. The role of mirk kinase in sarcomas. Sarcoma 2011;2011:260757.
19. Evangelista M, Lim TY, Lee J, Parker L, Ashique A, Peterson AS, et al. Kinome siRNA screen identifies regulators of ciliogenesis and hedge-hog signal transduction. Sci Signal 2008;1:ra7.
20. Franck N, Montembault E, Rome P, Pascal A, Cremet JY, Giet R. CDK11(p58) is required for centriole duplication and Plk4 recruitment to mitotic centrosomes. PLoS One 2011;6:e14600.
21. Tiedemann RE, Zhu YX, Schmidt J, Shi CX, Sereduk C, Yin H, et al. Identification of molecular vulnerabilities in human multiple myeloma cells by RNAi lethality screening of the druggable genome. Cancer Res 2012;72:757-68.
22. Feng Y, Qi W, Martinez J, Nelson MA. The cyclin-dependent kinase 11 interacts with 14-3-3 proteins. Biochem Biophys Res Commun 2005;331:1503-9.
23. Degenhardt Y, Lampkin T. Targeting Polo-like kinase in cancer therapy. Clin Cancer Res 2010;16:384-9.
24. Friedman E. Mirk/Dyrk1B in cancer. J Cell Biochem 2007;102:274-9.
25. Yamaguchi U, Honda K, Satow R, Kobayashi E, Nakayama R, Ichikawa H, et al. Functional genome screen for therapeutic targets of osteosarcoma. Cancer Sci 2009;100:2268-74.
26. Morales AG, Brassesco MS, Pezuk JA, Oliveira JC, Montaldi AP, Sakamoto-Hojo ET, et al. BI 2536-mediated PLK1 inhibition suppresses HOS and MG-63 osteosarcoma cell line growth and clonogenicity. Anticancer Drugs 2011;22:995-1001.
27. Liu X, Choy E, Hornicek FJ, Yang S, Yang C, Harmon D, et al.ROCK1 as a potential therapeutic target in osteosarcoma. J Orthop Res 2011;29:1259-66.
28. Loyer P, Busson A, Trembley JH, Hyle J, Grenet J, Zhao W, et al. The RNA binding motif protein 15B (RBM15B/OTT3) is a functional competitor of serine-arginine (SR) proteins and antagonizes the positive effect of the CDK11p110-cyclin L2alpha complex on splicing. J Biol Chem 2011;286:147-59.
29. Li T, Inoue A, Lahti JM, Kidd VJ. Failure to proliferate and mitotic arrest of CDK11(p110/p58)-null mutant mice at the blastocyst stage of embryonic cell development. Mol Cell Biol 2004;24:3188-97.
30. Wilkinson S, Croft DR, O'Prey J, Meedendorp A, O'Prey M, Dufes C, et al. The cyclin-dependent kinase PITSLRE/CDK11 is required for successful autophagy. Autophagy 2011;7:1295-301.
31. Feng Y, Shi J, Goldstein AM, Tucker MA, Nelson MA. Analysis of mutations and identification of several polymorphisms in the putative promoter region of the P34CDC2-related CDC2L1 gene located at 1P36 in melanoma cell lines and melanoma families. Int J Cancer 2002;99:834-8.
32. Martinsson T, Sjoberg RM, Hallstensson K, Nordling M, Hedborg F, Kogner P. Delimitation of a critical tumour suppressor region at distal 1p in neuroblastoma tumours. Eur J Cancer 1997;33:1997-2001.
33. Dave BJ, Pickering DL, Hess MM, Weisenburger DD, Armitage JO, Sanger WG. Deletion of cell division cycle 2-like 1 gene locus on 1p36 in non-Hodgkin lymphoma. Cancer Genet Cytogenet 1999;108:120-6.
34. White PS, Fujimori M, Marshall HN, Kaufman BA, Brodeur GM. Characterization of the region of consistent deletion within 1p36 in neuroblastomas. Prog Clin Biol Res 1994;385:3-9.
35. Petretti C, Savoian M, Montembault E, Glover DM, Prigent C, Giet R. The PITSLRE/CDK11p58 protein kinase promotes centrosome maturation and bipolar spindle formation. EMBO Rep 2006;7:418-24.
36. Naik S, Dothager RS, Marasa J, Lewis CL, Piwnica-Worms D. Vascular endothelial growth factor receptor-1 is synthetic lethal to aberrant {beta}-catenin activation in colon cancer. Clin Cancer Res 2009;15:7529-37.
37. Tiedemann RE, Zhu YX, Schmidt J, Yin H, Shi CX, Que Q, et al. Kinomewide RNAi studies in human multiple myeloma identify vulnerable kinase targets, including a lymphoid-restricted kinase, GRK6. Blood 2010;115:1594-604.
38. Cicenas J, Valius M. The CDK inhibitors in cancer research and therapy. J Cancer Res Clin Oncol 2011;137:1409-18.